Overview

BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

Status:
Completed

Trial end date:
2017-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) for the treatment of moderate to severe chronic plaque psoriasis in adult patients.

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie

Collaborator:

Boehringer Ingelheim

Treatments:

Antibodies, Monoclonal
Ustekinumab